NO20020684D0 - Aminopyrazolderivater, fremgangsmåte for deres fremstilling og deres anvendelse som antitumormidler - Google Patents

Aminopyrazolderivater, fremgangsmåte for deres fremstilling og deres anvendelse som antitumormidler

Info

Publication number: NO20020684D0
Authority: NO; Norway
Prior art keywords: processes; preparation; antitumor agents; aminopyrazole derivatives; aminopyrazole
Prior art date: 1999-08-12

Application number

NO20020684A

Other languages

English (en)

Other versions

NO20020684L (no

Inventor

Paolo Pevarello

Paolo Orsini

Gabriella Traquandi

Mario Varasi

Edward L Fritzen

Martha A Warpehoski

Betsy S Pierce

Maria Gabriella Brasca

Original Assignee

Upjohn Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-12

Filing date

2002-02-11

Publication date

2002-02-11

2002-02-11 Application filed by Upjohn Co filed Critical Upjohn Co

2002-02-11 Publication of NO20020684D0 publication Critical patent/NO20020684D0/no

2002-04-03 Publication of NO20020684L publication Critical patent/NO20020684L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Virology (AREA)
Psychiatry (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20020684A 1999-08-12 2002-02-11 3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler NO20020684L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US37283199A	1999-08-12	1999-08-12
PCT/US2000/006699 WO2001012189A1 (en)	1999-08-12	2000-05-05	3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents

Publications (2)

Publication Number	Publication Date
NO20020684D0 true NO20020684D0 (no)	2002-02-11
NO20020684L NO20020684L (no)	2002-04-03

Family

ID=23469802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20020684A NO20020684L (no)	1999-08-12	2002-02-11	3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler

Country Status (35)

Country	Link
US (2)	US7034049B1 (no)
EP (1)	EP1202733B1 (no)
JP (1)	JP2003507329A (no)
KR (1)	KR20020060160A (no)
CN (1)	CN1373662A (no)
AP (1)	AP2002002442A0 (no)
AR (1)	AR026122A1 (no)
AT (1)	ATE305782T1 (no)
AU (1)	AU4971400A (no)
BG (1)	BG106480A (no)
BR (1)	BR0013143A (no)
CA (1)	CA2383555C (no)
CZ (1)	CZ2002422A3 (no)
DE (1)	DE60023012T2 (no)
DK (1)	DK1202733T3 (no)
EA (1)	EA005373B1 (no)
EE (1)	EE200200065A (no)
ES (1)	ES2249270T3 (no)
GE (1)	GEP20053476B (no)
HK (1)	HK1046866A1 (no)
HR (1)	HRP20020128A2 (no)
HU (1)	HUP0203542A3 (no)
IL (1)	IL147923A0 (no)
IS (1)	IS6265A (no)
MA (1)	MA25493A1 (no)
MX (1)	MXPA02001498A (no)
NO (1)	NO20020684L (no)
NZ (1)	NZ517237A (no)
OA (1)	OA12046A (no)
PE (1)	PE20010130A1 (no)
PL (1)	PL353455A1 (no)
SK (1)	SK1812002A3 (no)
WO (1)	WO2001012189A1 (no)
YU (1)	YU9602A (no)
ZA (1)	ZA200201511B (no)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9901691D0 (en)	1999-01-26	1999-03-17	Cerebrus Ltd	Chemical compounds
EE200200065A (et) *	1999-08-12	2003-04-15	Pharmacia Italia S.P.A.	3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon
AU2972701A (en)	2000-02-07	2001-08-14	Bristol Myers Squibb Co	3-aminopyrazole inhibitors of cyclin dependent kinases
ES2236217T3 (es)	2000-04-25	2005-07-16	Bristol-Myers Squibb Company	Uso de 5.tio.,sulfinil- y sulfonilpirazolo 3,4-b)-piridinas como inhibidores de la quinasa dependiente de la ciclina.
DE10037310A1 (de) *	2000-07-28	2002-02-07	Asta Medica Ag	Neue Indolderivate und deren Verwendung als Arzneimittel
CZ2003468A3 (cs) *	2000-08-31	2004-05-12	Pfizeráproductsáinc	Deriváty pyrazolu a jejich použití jako inhibitorů proteinkinázy
US20020103185A1 (en) *	2000-08-31	2002-08-01	Sanner Mark A.	Pyrazole derivatives
JP2004517840A (ja) *	2000-11-27	2004-06-17	フアルマシア・イタリア・エツセ・ピー・アー	フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用
US6455559B1 (en) *	2001-07-19	2002-09-24	Pharmacia Italia S.P.A.	Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
NZ527767A (en) *	2001-01-26	2004-11-26	Pharmacia Italia S	Chromane derivatives, process for their preparation and their use as antitumor agents
JP2004526721A (ja) *	2001-03-02	2004-09-02	エフ．ホフマン−ラ　ロシュ　アーゲー	Ｉｐアンタゴニストとしてのアルコキシカルボニルアミノヘテロアリールカルボン酸誘導体
SE0100902D0 (sv) *	2001-03-15	2001-03-15	Astrazeneca Ab	Compounds
SE0100903D0 (sv) *	2001-03-15	2001-03-15	Astrazeneca Ab	Compounds
US6787555B2 (en)	2001-04-30	2004-09-07	The Procter & Gamble Company	Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6727364B2 (en)	2001-04-30	2004-04-27	The Procter & Gamble Company	Triazole compounds useful in treating diseases associated with unwanted cytokine activity
WO2002096426A1 (en)	2001-05-25	2002-12-05	Bristol-Myers Squibb Company	Hydantion derivatives as inhibitors of matrix metalloproteinases
DE10148618B4 (de) *	2001-09-25	2007-05-03	Schering Ag	Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148617A1 (de) *	2001-09-25	2003-04-24	Schering Ag	Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
ATE440094T1 (de) *	2001-09-27	2009-09-15	Equispharm Co Ltd	Fumagillolderivate und verfahren zu deren herstellung
SE0103710D0 (sv)	2001-11-07	2001-11-07	Astrazeneca Ab	Compounds
AU2002362030A1 (en) *	2001-11-27	2003-06-10	Fred Hutchinson Cancer Research Center	Methods for inhibiting deacetylase activity
SE0202539D0 (sv)	2002-08-27	2002-08-27	Astrazeneca Ab	Compounds
GB0221246D0 (en) *	2002-09-13	2002-10-23	Astrazeneca Ab	Compounds
US6593477B1 (en)	2002-10-29	2003-07-15	Eastman Kodak Company	Synthesis of 3-acylaminopyrazoles
EP1569929B9 (en) *	2002-12-10	2011-09-14	Virochem Pharma Inc.	Compounds and methods for the treatment or prevention of flavivirus infections
UA81790C2 (uk)	2002-12-19	2008-02-11	Фармация Италия С.П.А.	Заміщені піролопіразольні похідні як інгібітори кінази
AU2003294376A1 (en) *	2003-01-06	2004-08-10	Eli Lilly And Company	Heteroaryl compounds
PL378117A1 (pl) *	2003-02-11	2006-03-06	Prosidion Limited	Tricyklopodstawione związki amidowe
AU2004226479A1 (en) *	2003-03-27	2004-10-14	Evotec Oai	Ophthalmic compositions for treating ocular hypertension
SE0301446D0 (sv)	2003-05-16	2003-05-16	Astrazeneca Ab	New Compounds
AU2004240772B2 (en)	2003-05-22	2011-04-28	Nerviano Medical Sciences S.R.L.	Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors
WO2005009344A2 (en)	2003-06-05	2005-02-03	Elan Pharmaceuticals, Inc.	Acylated amino acid amidyl pyrazoles and related compounds
US7141568B2 (en)	2003-07-09	2006-11-28	Pfizer Italia S.R.L.	Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
BRPI0414313A (pt)	2003-09-11	2006-11-07	Kemia Inc	inibidores de citocinas
JP2007517905A (ja) *	2004-01-16	2007-07-05	ワイス	アゾールを含有するベータアミロイド産生のヘテロ環式スルホンアミド阻害剤
WO2005072731A1 (en) *	2004-01-29	2005-08-11	X-Ceptor Therapeutics, Inc.	3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
CN1938279B (zh) *	2004-01-30	2011-09-14	沃泰克斯药物股份有限公司	Atp-结合弹夹转运蛋白调控剂
TW200526204A (en)	2004-02-03	2005-08-16	Pharmacia Italia Spa	1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
WO2005118543A1 (ja) *	2004-06-03	2005-12-15	Ono Pharmaceutical Co., Ltd.	キナーゼ阻害薬およびその用途
SE0401762D0 (sv) *	2004-07-05	2004-07-05	Astrazeneca Ab	Novel compounds
US7648992B2 (en)	2004-07-05	2010-01-19	Astrazeneca Ab	Hydantoin derivatives for the treatment of obstructive airway diseases
US8148412B2 (en) *	2004-12-03	2012-04-03	Novo Nordisk A/S	Heteroaromatic glucokinase activators
SE0403085D0 (sv)	2004-12-17	2004-12-17	Astrazeneca Ab	Novel componds
SE0403086D0 (sv)	2004-12-17	2004-12-17	Astrazeneca Ab	Compounds
US7361672B2 (en) *	2004-12-23	2008-04-22	Hoffmann-La Roche Inc.	Heteroarylacetamide inhibitors of factor Xa
FR2880540B1 (fr) *	2005-01-13	2008-07-11	Aventis Pharma Sa	Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
WO2008007113A2 (en) *	2006-07-14	2008-01-17	Astex Therapeutics Limited	Pharmaceutical combinations
CA2613303C (en) *	2005-07-11	2012-06-19	Mitsubishi Tanabe Pharma Corporation	An oxime derivative for use as a glucokinase activator
WO2007009898A1 (en)	2005-07-19	2007-01-25	Nerviano Medical Sciences S.R.L.	1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
AU2006295260A1 (en) *	2005-08-29	2007-04-05	Gerard M. Housey	Theramutein modulators
AR058705A1 (es)	2005-12-23	2008-02-20	Astrazeneca Ab	Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1)
WO2007081966A2 (en) *	2006-01-09	2007-07-19	University Of Southern California	Small molecules for treating cancer and abnormal cell proliferation disorders
WO2007095383A2 (en) *	2006-02-15	2007-08-23	Myriad Genetics, Inc.	Prodrugs
UY30183A1 (es) *	2006-03-02	2007-10-31	Astrazeneca Ab	Derivados de quinolina
US8211925B2 (en) *	2006-04-28	2012-07-03	Transtech Pharma, Inc.	Benzamide glucokinase activators
CN101484438A (zh) *	2006-05-03	2009-07-15	阿斯利康(瑞典)有限公司	吡唑衍生物及其作为p13k抑制剂的用途
TWI433839B (zh)	2006-08-11	2014-04-11	Neomed Inst	新穎的苯并咪唑衍生物290
TW200831488A (en) *	2006-11-29	2008-08-01	Astrazeneca Ab	Novel compounds
US7737149B2 (en)	2006-12-21	2010-06-15	Astrazeneca Ab	N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
JP5207981B2 (ja)	2007-01-10	2013-06-12	田辺三菱製薬株式会社	ヒドラゾン誘導体
WO2008084873A1 (ja) *	2007-01-10	2008-07-17	Mitsubishi Tanabe Pharma Corporation	オキシム誘導体
WO2008104994A2 (en) *	2007-02-28	2008-09-04	Advinus Therapeutics Private Limited	2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
KR100923540B1 (ko) *	2007-11-23	2009-10-27	한국과학기술연구원	5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법
BRPI0914233A2 (pt) *	2008-06-19	2015-11-03	Astrazeneca Ab	composto, uso de um composto, métodos para produzir um efeito inibidor de fgfr e para produzir um efeito anticâncer em um animal de sangue quente, composição farmacêutica, e, método para tratar uma doença
CA2729988C (en)	2008-07-10	2016-09-13	Pharma Ip General Incorporated Association	Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
WO2010009985A2 (en)	2008-07-24	2010-01-28	Nerviano Medical Sciences S.R.L.	Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
US20100160322A1 (en)	2008-12-04	2010-06-24	Abbott Laboratories	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en)	2008-12-04	2013-10-15	Abbvie Inc.	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en)	2008-12-05	2013-10-22	Abbvie Inc.	Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
KR101692705B1 (ko) *	2008-12-05	2017-01-04	애브비 인코포레이티드	암 및 면역 질환의 치료를 위한 Ｂｃｌ２선택적 아폽토시스-유도제로서의 설폰아미드 유도체
US8586754B2 (en)	2008-12-05	2013-11-19	Abbvie Inc.	BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CA2750565C (en) *	2009-01-30	2015-10-20	Glaxosmithkline Llc	Crystalline n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
US20120045459A1 (en) *	2009-05-05	2012-02-23	Van Andel Research Institute	Methods for Treating Autophagy-Related Disorders
CN102470127A (zh) *	2009-08-19	2012-05-23	埃姆比特生物科学公司	联芳基化合物和其使用方法
CN105153188B (zh)	2009-10-22	2018-06-01	法博太科制药有限公司	抗纤维化剂的稠环类似物
WO2011056916A1 (en) *	2009-11-05	2011-05-12	Lexicon Pharmaceuticals, Inc.	Tryptophan hydroxylase inhibitors for the treatment of cancer
SG10201502484SA (en) *	2010-03-30	2015-05-28	Verseon Corp	Multisubstituted aromatic compounds as inhibitors of thrombin
CN103108868B (zh)	2010-06-07	2015-11-25	诺沃梅迪科斯有限公司	呋喃基化合物及其用途
JP2013530180A (ja)	2010-06-16	2013-07-25	パーデュー、ファーマ、リミテッド、パートナーシップ	アリール置換インドールおよびその使用
CN105360132A (zh) *	2010-11-03	2016-03-02	陶氏益农公司	杀虫组合物和与其相关的方法
US9073895B2 (en) *	2010-12-16	2015-07-07	Boehringer Ingelheim International Gmbh	Biarylamide inhibitors of leukotriene production
CN103298816A (zh)	2010-12-17	2013-09-11	内尔维阿诺医学科学有限公司	作为激酶抑制剂的取代的吡唑并-喹唑啉衍生物
FR2978441A1 (fr) *	2011-07-25	2013-02-01	Diverchim	Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
AR087701A1 (es) *	2011-08-31	2014-04-09	Japan Tobacco Inc	Derivados de pirazol con actividad inhibidora de sglt1
ES2882807T3 (es) *	2011-09-16	2021-12-02	Novartis Ag	Heterociclil carboxamidas N-sustituidas
PH12014500930A1 (en)	2011-10-26	2014-06-09	Dow Agrosciences Llc	Pesticidal compositions and processes related thereto
US8901153B2 (en)	2012-04-27	2014-12-02	Dow Agrosciences, Llc.	Pesticidal compositions and processes related thereto
US9282739B2 (en)	2012-04-27	2016-03-15	Dow Agrosciences Llc	Pesticidal compositions and processes related thereto
US9708288B2 (en)	2012-04-27	2017-07-18	Dow Agrosciences Llc	Pesticidal compositions and processes related thereto
US20140179712A1 (en)	2012-12-21	2014-06-26	Astrazeneca Ab	Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
CN103936637B (zh) *	2013-01-18	2016-04-06	北京大学	E-3,4-二羟苯乙烯基亚砜类化合物的制备方法及其作为神经保护药物的应用
CN110101699A (zh)	2013-03-15	2019-08-09	维颂公司	作为丝氨酸蛋白酶抑制剂的多取代芳族化合物
EA029296B1 (ru)	2013-03-15	2018-03-30	Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед	Пиридиновые производные в качестве ингибиторов реаранжированной в процессе трансфекции (ret) киназы
HK1214252A1 (zh)	2013-03-15	2016-07-22	Verseon Corporation	作為凝血酶抑制劑的鹵代吡唑
US8937071B2 (en)	2013-03-15	2015-01-20	Glaxosmithkline Intellectual Property Development Limited	Compounds as rearranged during transfection (RET) inhibitors
WO2014170350A1 (en) *	2013-04-17	2014-10-23	Albert Ludwigs Universität Freiburg	Compounds for use as bromodomain inhibitors
CN103265535B (zh) *	2013-05-14	2015-06-17	浙江医药高等专科学校	抗肿瘤化合物、其制备方法和用途
HK1225718A1 (zh) *	2013-08-30	2017-09-15	Ambit Biosciences Corporation	联芳基乙酰胺化合物及其使用方法
EP3057426A4 (en)	2013-10-17	2017-03-29	Dow AgroSciences LLC	Processes for the preparation of pesticidal compounds
CA2925595A1 (en)	2013-10-17	2015-04-23	Dow Agrosciences Llc	Processes for the preparation of pesticidal compounds
JP2016535010A (ja)	2013-10-17	2016-11-10	ダウアグロサイエンシィズエルエルシー	有害生物防除性化合物の製造方法
MX2016004940A (es)	2013-10-17	2016-06-28	Dow Agrosciences Llc	Proceso para la preparacion de compuestos plaguicidas.
CN105636445B (zh)	2013-10-17	2018-12-07	美国陶氏益农公司	制备杀虫化合物的方法
WO2015058021A1 (en)	2013-10-17	2015-04-23	Dow Agrosciences Llc	Processes for the preparation of pesticidal compounds
CA2925952A1 (en)	2013-10-17	2015-04-23	Dow Agrosciences Llc	Processes for the preparation of pesticidal compounds
JP2016535025A (ja)	2013-10-22	2016-11-10	ダウアグロサイエンシィズエルエルシー	相乗的有害生物防除組成物および関連する方法
JP2016536307A (ja)	2013-10-22	2016-11-24	ダウアグロサイエンシィズエルエルシー	農薬組成物および関連する方法
KR20160074640A (ko)	2013-10-22	2016-06-28	다우 아그로사이언시즈 엘엘씨	살충 조성물 및 관련 방법
WO2015061163A1 (en)	2013-10-22	2015-04-30	Dow Agrosciences Llc	Pesticidal compositions and related methods
NZ719541A (en)	2013-10-22	2017-11-24	Dow Agrosciences Llc	Synergistic pesticidal compositions and related methods
EP3062619B1 (en)	2013-10-22	2019-07-24	Dow AgroSciences LLC	Pesticidal compositions and related methods
AU2014340412B2 (en)	2013-10-22	2017-04-20	Dow Agrosciences Llc	Synergistic pesticidal compositions and related methods
MX2016005310A (es)	2013-10-22	2016-08-08	Dow Agrosciences Llc	Composiciones pesticidas sinergicas y metodos relacionados.
JP2016535024A (ja)	2013-10-22	2016-11-10	ダウアグロサイエンシィズエルエルシー	相乗的有害生物防除組成物および関連する方法
NZ720023A (en)	2013-10-22	2017-09-29	Dow Agrosciences Llc	Synergistic pesticidal compositions and related methods
TW201519786A (zh)	2013-10-22	2015-06-01	陶氏農業科學公司	殺蟲組成物及相關方法（一）
EP3060050A4 (en)	2013-10-22	2017-04-05	Dow AgroSciences LLC	Synergistic pesticidal compositions and related methods
JP2016534068A (ja)	2013-10-22	2016-11-04	ダウアグロサイエンシィズエルエルシー	相乗的有害生物防除組成物および関連する方法
JP2016538265A (ja)	2013-10-22	2016-12-08	ダウアグロサイエンシィズエルエルシー	相乗的有害生物防除組成物および関連する方法
KR20160074581A (ko)	2013-10-22	2016-06-28	다우 아그로사이언시즈 엘엘씨	상승작용적 살충 조성물 및 관련 방법
NZ719754A (en)	2013-10-22	2017-06-30	Dow Agrosciences Llc	Synergistic pesticidal compositions and related methods
CA2926433A1 (en)	2013-10-22	2015-04-30	Dow Agrosciences Llc	Pesticidal compositions and related methods
WO2015143653A1 (en) *	2014-03-26	2015-10-01	Merck Sharp & Dohme Corp.	TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
KR20170039121A (ko)	2014-07-31	2017-04-10	다우 아그로사이언시즈 엘엘씨	3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
JP2017523168A (ja)	2014-07-31	2017-08-17	ダウアグロサイエンシィズエルエルシー	３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの製造方法
CN106488909A (zh)	2014-07-31	2017-03-08	美国陶氏益农公司	制备3‑(3‑氯‑1h‑吡唑‑1‑基)吡啶的方法
KR20170042714A (ko)	2014-08-19	2017-04-19	다우 아그로사이언시즈 엘엘씨	3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
HUE044604T2 (hu)	2014-09-10	2019-11-28	Glaxosmithkline Ip Dev Ltd	Piridin-származékok mint transzfekció alatt átrendezõdött (RET) kináz inhibitorok
US9879021B2 (en)	2014-09-10	2018-01-30	Glaxosmithkline Intellectual Property Development Limited	Compounds as rearranged during transfection (RET) inhibitors
JP2017528469A (ja)	2014-09-12	2017-09-28	ダウアグロサイエンシィズエルエルシー	３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの調製方法
BR112017004704A2 (pt)	2014-09-17	2018-01-23	Verseon Corp	composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
GB201416513D0 (en) *	2014-09-18	2014-11-05	Astex Therapeutics Ltd And Cancer Res Technology Ltd	Pharmaceutical compounds
PL3261639T3 (pl)	2015-02-27	2022-12-19	Verseon International Corporation	Podstawione związki pirazolowe jako inhibitory proteazy serynowej
EP3268000B1 (en)	2015-03-09	2021-08-04	Aurigene Discovery Technologies Limited	Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
HK1251972A1 (zh)	2015-05-06	2019-05-10	The Regents Of The University Of California	K-ras调节剂
SI3302448T1 (sl)	2015-06-04	2024-03-29	Aurigene Oncology Limited	Substituirani heterociklični derivati kot inhibitorji cdk
ES2914526T3 (es) *	2016-08-12	2022-06-13	Athenex Inc	Composiciones de biarilo y métodos para modular una cascada de cinasa
WO2018125817A1 (en)	2016-12-29	2018-07-05	Dow Agrosciences Llc	Processes for the preparation of pesticidal compounds
BR112019008372B1 (pt)	2016-12-29	2021-11-09	Dow Agrosciences Llc	Processo para preparação de compostos pesticidas
CN110114349B (zh) *	2016-12-29	2022-03-15	埃尼奥制药公司	作为抗病毒剂的噻吩衍生物
EP3577103A1 (en)	2017-02-03	2019-12-11	Certa Therapeutics Pty Ltd.	Anti-fibrotic compounds
CA3056886A1 (en)	2017-03-21	2018-09-27	Arbutus Biopharma Corporation	Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
MA50014A (fr) *	2017-04-20	2020-07-08	Leidos Biomedical Res Inc	Modulateurs de k-ras
US11040945B2 (en)	2017-12-06	2021-06-22	Lin Bioscience Pty Ltd.	Tubulin inhibitors
JP7184383B2 (ja) *	2018-02-01	2022-12-06	ザ・ユニバーシティ・オブ・シドニー	抗癌性化合物
AU2019247885B2 (en) *	2018-04-04	2023-09-07	Aurigene Oncology Limited	Substituted pyrazole derivatives as selective CDK12/13 inhibitors
WO2020142559A1 (en)	2018-12-31	2020-07-09	Biomea Fusion, Llc	Inhibitors of menin-mll interaction
AU2019417833B2 (en)	2018-12-31	2024-11-07	Biomea Fusion, Inc.	Irreversible inhibitors of menin-MLL interaction
EP4096657A4 (en) *	2020-01-29	2024-07-10	Foghorn Therapeutics Inc.	Compounds and uses thereof
CN111793034B (zh) *	2020-07-24	2021-11-19	华中科技大学	苯并咪唑盐衍生物与制备抗肿瘤药物的应用
CA3194868A1 (en) *	2020-10-16	2022-04-21	Georg Winter	Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2022135442A1 (zh) *	2020-12-22	2022-06-30	上海拓界生物医药科技有限公司	Cdk2抑制剂及其制备方法
CA3228627A1 (en)	2021-08-11	2023-02-16	Thomas Butler	Covalent inhibitors of menin-mll interaction for diabetes mellitus
AU2022331496A1 (en)	2021-08-20	2024-02-29	Biomea Fusion, Inc.	Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
MX2024007062A (es) *	2021-12-10	2024-07-19	Prothena Biosciences Ltd	Compuestos heterociclicos como inhibidores de dyrk1a.
WO2023203172A1 (en) *	2022-04-20	2023-10-26	Proxygen Gmbh	Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2024155710A1 (en)	2023-01-18	2024-07-25	Biomea Fusion, Inc.	Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
CN116496151B (zh) *	2023-04-26	2024-08-23	长沙医学院	一种利用Catellani策略制备芴酮衍生物的方法
CN118221668A (zh) *	2024-03-19	2024-06-21	华南农业大学	一种含2-氨基-1,3,4-噻二唑的吲哚美辛衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5162360A (en)	1991-06-24	1992-11-10	Warner-Lambert Company	2-heteroatom containing urea and thiourea ACAT inhibitors
ES2219670T3 (es)	1994-11-10	2004-12-01	Millennium Pharmaceuticals, Inc.	Utilizacion de compuestos de pirazola para el tratamiento de la glomerulonefritis, cancer, ateroesclerosis o restenosis.
WO1998024768A1 (en)	1996-12-03	1998-06-11	Banyu Pharmaceutical Co., Ltd.	Novel urea derivatives
CA2288787A1 (en)	1997-05-22	1998-11-26	G.D. Searle And Co.	Pyrazole derivatives as p38 kinase inhibitors
SK285371B6 (sk) *	1997-12-22	2006-12-07	Bayer Corporation	Aryl- a heteroaryl-substituované heterocyklické močoviny, ich použitie a farmaceutické kompozície sich obsahom
DE1041982T1 (de)	1997-12-22	2001-06-07	Bayer Corp., Pittsburgh	HEMMUNG DER p38 KINASE AKTIVITÄT DURCH SUBSTITUIERTEN HETEROCYCLISCHEN HARNSTOFFEN
EE200200065A (et) *	1999-08-12	2003-04-15	Pharmacia Italia S.P.A.	3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon
US6455559B1 (en) *	2001-07-19	2002-09-24	Pharmacia Italia S.P.A.	Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents

2000
- 2000-05-05 EE EEP200200065A patent/EE200200065A/xx unknown
- 2000-05-05 GE GE4758A patent/GEP20053476B/en unknown
- 2000-05-05 HU HU0203542A patent/HUP0203542A3/hu unknown
- 2000-05-05 EP EP00931906A patent/EP1202733B1/en not_active Expired - Lifetime
- 2000-05-05 CZ CZ2002422A patent/CZ2002422A3/cs unknown
- 2000-05-05 EA EA200200248A patent/EA005373B1/ru not_active IP Right Cessation
- 2000-05-05 HK HK02108532.6A patent/HK1046866A1/zh unknown
- 2000-05-05 WO PCT/US2000/006699 patent/WO2001012189A1/en not_active Ceased
- 2000-05-05 PL PL00353455A patent/PL353455A1/xx not_active Application Discontinuation
- 2000-05-05 DE DE60023012T patent/DE60023012T2/de not_active Expired - Fee Related
- 2000-05-05 MX MXPA02001498A patent/MXPA02001498A/es active IP Right Grant
- 2000-05-05 OA OA1200200051A patent/OA12046A/en unknown
- 2000-05-05 DK DK00931906T patent/DK1202733T3/da active
- 2000-05-05 AU AU49714/00A patent/AU4971400A/en not_active Abandoned
- 2000-05-05 HR HR20020128A patent/HRP20020128A2/hr not_active Application Discontinuation
- 2000-05-05 CN CN00812732A patent/CN1373662A/zh active Pending
- 2000-05-05 KR KR1020027001857A patent/KR20020060160A/ko not_active Withdrawn
- 2000-05-05 BR BR0013143-1A patent/BR0013143A/pt not_active Application Discontinuation
- 2000-05-05 YU YU9602A patent/YU9602A/sh unknown
- 2000-05-05 IL IL14792300A patent/IL147923A0/xx unknown
- 2000-05-05 AT AT00931906T patent/ATE305782T1/de not_active IP Right Cessation
- 2000-05-05 NZ NZ517237A patent/NZ517237A/xx unknown
- 2000-05-05 JP JP2001516535A patent/JP2003507329A/ja not_active Withdrawn
- 2000-05-05 SK SK181-2002A patent/SK1812002A3/sk unknown
- 2000-05-05 AP APAP/P/2002/002442A patent/AP2002002442A0/en unknown
- 2000-05-05 US US10/048,486 patent/US7034049B1/en not_active Expired - Fee Related
- 2000-05-05 ES ES00931906T patent/ES2249270T3/es not_active Expired - Lifetime
- 2000-05-05 CA CA002383555A patent/CA2383555C/en not_active Expired - Fee Related
- 2000-05-15 PE PE2000000453A patent/PE20010130A1/es not_active Application Discontinuation
- 2000-05-16 AR ARP000102347A patent/AR026122A1/es unknown
- 2000-09-22 US US09/667,603 patent/US6218418B1/en not_active Expired - Fee Related
2002
- 2002-02-11 NO NO20020684A patent/NO20020684L/no not_active Application Discontinuation
- 2002-02-11 IS IS6265A patent/IS6265A/is unknown
- 2002-02-22 ZA ZA200201511A patent/ZA200201511B/xx unknown
- 2002-03-05 BG BG06480A patent/BG106480A/xx unknown
- 2002-03-11 MA MA26549A patent/MA25493A1/fr unknown

Also Published As

Publication number	Publication date
EE200200065A (et)	2003-04-15
CA2383555A1 (en)	2001-02-22
PE20010130A1 (es)	2001-02-01
HRP20020128A2 (en)	2003-04-30
US7034049B1 (en)	2006-04-25
EP1202733A1 (en)	2002-05-08
AR026122A1 (es)	2003-01-29
ZA200201511B (en)	2003-05-28
HK1046866A1 (zh)	2003-01-30
DK1202733T3 (da)	2005-10-31
YU9602A (sh)	2004-11-25
HUP0203542A2 (en)	2003-05-28
MA25493A1 (fr)	2002-07-01
AU4971400A (en)	2001-03-13
IL147923A0 (en)	2002-08-14
ATE305782T1 (de)	2005-10-15
GEP20053476B (en)	2005-03-25
IS6265A (is)	2002-02-11
WO2001012189A1 (en)	2001-02-22
US6218418B1 (en)	2001-04-17
PL353455A1 (en)	2003-11-17
WO2001012189A8 (en)	2001-08-02
EP1202733A4 (en)	2003-05-14
CZ2002422A3 (cs)	2002-11-13
EA200200248A1 (ru)	2002-08-29
NO20020684L (no)	2002-04-03
NZ517237A (en)	2004-02-27
DE60023012T2 (de)	2006-07-20
ES2249270T3 (es)	2006-04-01
HUP0203542A3 (en)	2003-07-28
BG106480A (en)	2002-09-30
EP1202733B1 (en)	2005-10-05
OA12046A (en)	2006-05-02
KR20020060160A (ko)	2002-07-16
MXPA02001498A (es)	2003-07-21
BR0013143A (pt)	2002-06-11
CA2383555C (en)	2009-02-17
CN1373662A (zh)	2002-10-09
SK1812002A3 (en)	2003-02-04
AP2002002442A0 (en)	2002-03-31
JP2003507329A (ja)	2003-02-25
DE60023012D1 (de)	2006-02-16
EA005373B1 (ru)	2005-02-24

Publication	Publication Date	Title
NO20020684D0 (no)	2002-02-11	Aminopyrazolderivater, fremgangsmåte for deres fremstilling og deres anvendelse som antitumormidler
NO20012058D0 (no)	2001-04-26	2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
NO20012057D0 (no)	2001-04-26	2-amino-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
DK1204649T3 (da)	2007-12-03	Arylmethylcarbonylaminothiazolderivater og deres anvendelse som antitumormidler
NO20020687D0 (no)	2002-02-11	3(5)-ureidopyrazolderivater, fremgangsmåte for fremstilling av disse og deres anvendelse som antitumormidler
DK1368349T3 (da)	2007-05-21	Xanthinderivater, deres fremstilling og deres anvendelse som lægemidler
NO20020811D0 (no)	2002-02-19	Sulfonylkarboksamidderivater, fremgangsmåte for deres fremstilling og deres anvendelse som legemidler
NO20025150D0 (no)	2002-10-25	2-acylindolderivater og deres anvendelse som antitumormidler
NO20014013D0 (no)	2001-08-17	16-halogenepotilonderivater, fremgangsmater for fremstilling av dem og deres farmasoytiske anvendelse
DK1083171T3 (da)	2004-08-09	Pyrazolinderivater, deres fremstilling og anvendelse som medikamenter
NO20025879L (no)	2003-01-29	Acylfenylureaderivater, fremgangsmåter for fremstilling derav og deres anvendelse som legemiddel
NO963506D0 (no)	1996-08-22	4-Heterocyklyl-substituerte kinazolin-derivater, fremgangsmåte for fremstilling derav og deres anvendelse som anti-kreftmidler
DK1095025T3 (da)	2003-04-07	Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
NO20021253L (no)	2002-04-24	Kinolylpropylpiperidinderivater og deres anvendelse som antibakterielle midler
DK1370550T3 (da)	2007-09-03	Quinolylpropylpiperidinderivater, deres fremstilling og præparater indeholdende dem
NO20040210L (no)	2004-03-03	Fenylacetamido-tiazolderivater, fremgangsmate for deres fremstilling og deres anvendelse som antitumormidler
NO985307D0 (no)	1998-11-13	Distamycinderivater, fremgangsmÕte for deres fremstilling, og deres anvendelse som antitumor- og antivirale midler
DK1043307T3 (da)	2003-09-22	3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
DK1387838T3 (da)	2006-08-14	Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO20016404L (no)	2002-03-01	Naftyridinderivater, fremgangsmåter for deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
NO20035486D0 (no)	2003-12-10	Benzodiazepinderivater og deres anvendelse som AMPA- reseptorstimulatorer
NO20002959D0 (no)	2000-06-09	Echinocandinderivater, fremgangsmÕte for fremstilling av slike og deres anvendelse som anti-soppmidler
DK1373249T3 (da)	2005-08-22	Imidazolidinderivater, deres fremstilling og deres anvendelse som anti-inflammatorisk middel
NO20001782L (no)	2000-10-09	3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
NO20033965L (no)	2003-09-08	Caloporosidderivater, fremgangsmåte for deres fremstilling og deres anvendelse

Legal Events

Date	Code	Title	Description
2006-07-31	FC2A	Withdrawal, rejection or dismissal of laid open patent application